Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology. More than a decade ago, Amgen introduced two of the first biologically derived human therapeutics, EPOGEN® (Epoetin alfa) and NEUPOGEN® (Filgrastim), which became the biotechnology industry's first blockbusters. These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic kidney disease and cancer.
Today, Amgen is a Fortune 500 company whose business has expanded to serve patients around the world in supportive cancer care as well as the treatment of anemia, rheumatoid arthritis and other autoimmune diseases such as psoriatic arthritis and ankylosing spondylitis. Amgen continues to sustain a culture rooted in biotechnology entrepreneurialism and innovation. As a science-based and patient-focused organization, we will follow the science wherever it may lead, to best treat serious illness.
Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine and dramatically improve the quality of people's lives.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.